Onchilles Pharma
PrivateLast Round
Series A
Extension
Nov 7, 2025
Total Funding Raised
$36.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Onchilles Pharma is a biotechnology company that develops first-in-class cytotoxic therapeutics designed to selectively kill cancer cells while preserving and activating immune function by harnessing the ELANE pathway.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Onchilles Pharma Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Onchilles Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 7, 2025 | ||||
| Series A | Jun 10, 2021 | ||||
| Seed | Jul 10, 2020 | ||||
| Grant | Dec 6, 2017 |
Onchilles Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCM Ventures | Series A Extension |
| Lincoln Park Capital | Series A Extension |
| Kennedy Lewis Investment Management | Series A Extension |
| LYZZ Capital | Series A Extension, Series A |
| InVivium Capital | Series A Extension |
| NuFund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Presenting a trial in progress poster at ASCO Annual Meeting.
- Mar 17, 2026
New preclinical data on NEU-002 program to be presented at AACR 2026.
Onchilles Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Onchilles Pharma's valuation, stock price, and market status.